101
CORDLIFE GROUP LIMITED
| ANNUAL REPORT 2015
NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2015
14.
INTANGIBLE ASSETS
(CONTINUED)
Amortisation expense
The amortisation of the intangible assets has been recognised in the “Administrative expenses” line item in
the consolidated statement of comprehensive income.
Note
Club
membership
Computer
software
Work in
progress
Total
$’000
$’000
$’000
$’000
Company
Cost:
At 1 July 2013
–
334
–
334
Additions
–
15
290
305
Transfer from property,
plant and equipment
12
–
69
–
69
At 30 June 2014 and
1 July 2014
–
418
290
708
Additions
186
53
583
822
At 30 June 2015
186
471
873
1,530
Accumulated amortisation:
At 1 July 2013
–
198
–
198
Amortisation for the year
–
86
–
86
At 30 June 2014 and
1 July 2014
–
284
–
284
Amortisation for the year
–
82
–
82
At 30 June 2015
–
366
–
366
Net carrying amount:
At 30 June 2014
–
134
290
424
At 30 June 2015
186
105
873
1,164
15.
FINANCIAL ASSET DESIGNATED AT FAIR VALUE THROUGH PROFIT OR LOSS
Group
Company
2015
2014
2015
2014
$’000
$’000
$’000
$’000
Quoted equity investment
60,858
50,494
60,858
50,494
As at 30 June 2015, the Group has a 9.13%* (2014: 10.02%) interest in China Cord Blood Corporation (“CCBC”),
a cord blood banking company listed on the New York Stock Exchange. The carrying value of the investment
is based on the last traded price as at 30 June 2015 (2014: 30 June 2014).
This investment is a financial asset designated at fair value through profit or loss in accordance with the
Group’s Risk Management and Investment Strategy (the “Strategy”).
* Cordlife’s interest in CCBC decreased during the financial year from 10.02% to 9.13% as a result of an issuance of restricted share units
to selected members of the CCBC management team.
